Los Angeles Capital Management LLC Has $2.89 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Los Angeles Capital Management LLC increased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 33.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 123,401 shares of the biopharmaceutical company’s stock after purchasing an additional 31,124 shares during the period. Los Angeles Capital Management LLC owned about 0.08% of TG Therapeutics worth $2,886,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new stake in shares of TG Therapeutics in the second quarter worth $8,698,000. Marshall Wace LLP acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at about $36,501,000. Raymond James & Associates lifted its position in shares of TG Therapeutics by 35.9% in the third quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company’s stock worth $3,980,000 after purchasing an additional 44,972 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of TG Therapeutics by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock worth $8,960,000 after purchasing an additional 59,523 shares during the period. Finally, Cetera Advisors LLC purchased a new position in TG Therapeutics during the first quarter valued at approximately $622,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $30.91 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The stock has a market capitalization of $4.79 billion, a P/E ratio of -309.07 and a beta of 2.19. The business has a 50-day moving average of $24.15 and a two-hundred day moving average of $20.79. TG Therapeutics, Inc. has a fifty-two week low of $9.81 and a fifty-two week high of $32.48.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.65% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same period in the previous year, the company earned $0.73 EPS. The firm’s revenue for the quarter was down 49.4% compared to the same quarter last year. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

TGTX has been the subject of a number of research reports. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright upped their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.50% of the stock is owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.